HR and breast cancer: Therefore, consideration of the role of CDK4/6i after prior CDK4/6i exposure should be regarded cautiously, taking into account the complex mechanism implicated in therapy resistance to these cell cycle checkpoint inhibitors and considering the expanding available therapies in patients with HR+/HER2- metastatic BC.